Randomized Study of Obicetrapib in Combination With Ezetimibe

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

Also called NCT04770389

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04770389
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04770389. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-23 (actual); primary completion 2021-05-07 (actual). Results posted on 2024-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Study of Obicetrapib in Combination With Ezetimibe
Acronym
OCEAN
Condition
Dyslipidemias
Condition
High Cholesterol
Condition
Hypercholesterolemia
Intervention (Drug)
Obicetrapib 5mg
Intervention (Drug)
Ezetimibe 10mg
Intervention (Other)
Placebo
Lead sponsor
NewAmsterdam Pharma (class: industry)

Record details

Record id
cardio:ct-nct04770389
Content hash
d85f2e646d5fac8f7d0e2b1880f9ebf54abde2afd54ce6d8fb3ee86786ca9f67